Comparison of Gd(DTPA-BMA) (Omniscan) versus Gd(HP-DO3A) (ProHance) relative-to gadolinium retention in human bone tissue by inductively coupled plasma mass spectroscopy
Comparison of Gd(DTPA-BMA) (Omniscan) versus Gd(HP-DO3A) (ProHance) relative-to gadolinium retention in human bone tissue by inductively coupled plasma mass spectroscopy
复制标题
DOI：
10.1097/01.rli.0000186569.32408.95
复制
发表时间：
2006-03-01
影响因子：
6.7
通讯作者：
Tweedle, MF
中科院分区：
文献类型：
--
作者：
White, GW;Gibby, WA;Tweedle, MF
目的：本研究的目的是测定两种临床剂量的Gd造影剂普朗斯和Omniscan在人体骨组织中的残留浓度。材料和方法：对髋关节置换手术患者注射0.1 mmol/kg的Gd螯合物后，采集骨标本进行分析，并与年龄匹配的无Gd螯合物注射的对照组进行比较。新鲜采集骨标本，冷藏，然后冷冻。粉碎和冷冻干燥后，用聚四氟乙烯炸弹和浓硝酸进行组织消化。建立了一种分析骨样品中Gd的方法，并用电感耦合等离子体质谱(ICP-MS)对其进行了验证。结果：将结果与以前使用不同技术分析相同组织样品的结果进行了比较。用电感耦合等离子体质谱测得组织保留率：Omniscan为1.77+/-0.704微克Gd/g骨(n=9)，Prohance为0.477+/-0.271微克Gd/g骨(n=10)。结论：Omniscan(Gd[DTPA-BMA])在骨骼中残留的Gd比ProHance(Gd[HP-DO3A])多约4倍(先前研究为2.5倍)。
Objective: The objective of this study was to determine the gadolinium (Gd) concentration remaining in human bone tissue after administration of standard clinical doses of 2 Gd-based contrast agents: Prol-lance and Omniscan.Materials and Methods: After administration of 0.1 mmol/kg of Gd chelate to patients undergoing hip replacement surgery, bone specimens were collected and analyzed, and compared with an age-matched control population without a history of Gd chelate administration. Bone specimens were collected fresh, refrigerated, and subsequently frozen. After grinding and freeze-drying, tissue digestion was performed using Teflon bombs and concentrated nitric acid. A method for analysis of Gd in bone specimens was developed and validated using inductively coupled plasma mass spectroscopy (ICP-MS).Results: Results were compared with a previous study using a different technique for analysis of the same tissue specimens. Tissue retention was 1.77 +/- 0.704 mu g Gd/g bone (n = 9) for Omniscan and 0.477 +/- 0.271 mu g Gd/g bone (n = 10) for ProHance measured by ICP-MS. These findings confirmed results from the previous ICP-AES study.Conclusion: Omniscan (Gd[DTPA-BMA]) left approximately 4 times (previous study 2.5 times) more Gd behind in bone than did ProHance (Gd[HP-DO3A]).